Total Hip Replacement
Conditions
Brief summary
This study is designed to compare the effect of IPC on post-operative circulation in lower limbs with gekoTM device after total hip replacement procedure.
Interventions
DEVICEgeko
neuromuscular electrostimulator
DEVICEIPC-Calf
IPC used on calf with or without geko
Sponsors
Firstkind Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male and Female 2. Aged over 18-80 years 3. Be in good general health and fitness other than the clinical requirement for a planned hip replacement. 4. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders. 5. No history or signs of drug abuse (including alcohol), licit or illicit. 6. Has not used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator (PI) during the thirty (30) days preceding the study. 7. Able to understand the Patient Information Sheet and willing to sign the written Informed Consent Form. 8. Able and willing to follow the protocol requirements.
Exclusion criteria
1. Are requiring hip revision surgery 2. History or signs of significant haematological disorders (especially in relation to clotting or coagulation or previous deep or superficial vein thrombosis/pulmonary embolism). 3. Significant Peripheral arterial disease (ABPI \< 0.8), varicose veins or lower limb ulceration or ischemia. 4. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement). 5. Recent trauma to lower limb. 6. Chronic Obesity (BMI Index \>40kg/m2). 7. Pregnancy. 8. Significant history of following diseases i. Cardiovascular: Recent MI (\< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (\< 3 months for Bare metal stent (BMS) and \< 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs ix. Haematological conditions i.e. coagulation disorders, sickle cell disease 9. A pulse rate of less than 40 beats/minute 10. A sitting systolic blood pressure \>180 and \<100 mmHg and/or a sitting diastolic pressure of \>100 mmHg. 11. Any significant illness during the four (4) weeks preceding the hip replacement surgery. 12. Participation in any clinical study during the eight (8) weeks preceding the screening period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultra sound measurements of haemodynamics | 10mins |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse event rate | 3 hrs | — |
| patient rated tolerability | 3 hrs | A questionnaire has been designed to record the opinion of the patient with regard to both devices, in particular how comfortable the devices were to wear. The patient will be asked to rate how comfortable the devices are to wear on a scale of 1-5, 1 being very comfortable and 5 being extremely uncomfortable |
Outcome results
None listed